Login
Intellia Therapeutics NASDAQ: NTLA
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
| Name | Intellia Therapeutics |
| Ticker | NTLA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
|
Price
52W Low/High |
51.81
9.44 / 83.68 |
| Momentum | Weak Down |
| Market cap | 3.1 B |
| 1Y Total Return |
256.82%
Strong |
| 1Y Volatility |
91.39%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
Details
| Ticker | NTLA |
| Name | Intellia Therapeutics |
| ISIN | US45826J1051 |
| CUSIP | 45826J105 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 3/5/21
| Close Price | 51.81 |
| 52W Low/High | 9.44 / 83.68 |
| Market cap | 3.1 B |
| 1Y Total Return |
256.82%
Strong |
| 1Y Volatility |
91.39%
High Risk |
| Beta | 3.52 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -231.5% |
| Cash from Op. / Cur. Liabilities | -0.78 |
| Diluted Earnings / Share | -2.40 |
| ROE | - |
| ROIC | -38.7% |
| Price / Revenue | 50.0 |
| Price / Book | 5.5 |
| Price / CF | -58.1 |
| Current Ratio | 9.6 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.07 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
58
|
43
|
30
|
26
|
16
|
6
|
|
| Gross Profit |
58
|
43
|
30
|
26
|
16
|
6
|
|
| R&D |
150
|
108
|
89
|
68
|
32
|
11
|
|
| EBITDA |
-128
|
-94
|
-81
|
-65
|
-31
|
-13
|
|
| Operating Income |
-137
|
-106
|
-91
|
-70
|
-32
|
-13
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
56
|
47
|
43
|
36
|
22
|
0
|
|
| EPS exc. Extra |
-2.40
|
-2.11
|
-1.98
|
-1.88
|
-1.42
|
-51.02
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
676
|
334
|
347
|
376
|
299
|
82
|
|
| Cash, Eq & Invt ShortTerm |
597
|
280
|
314
|
341
|
273
|
76
|
|
| Total Current Assets |
617
|
289
|
325
|
355
|
281
|
78
|
|
| Total Non-Current Assets |
60
|
45
|
22
|
21
|
18
|
5
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
149
|
64
|
69
|
76
|
89
|
103
|
|
| Total Current Liabilities |
64
|
36
|
41
|
31
|
31
|
11
|
|
| Long Term Debt |
85
|
29
|
29
|
44
|
58
|
93
|
|
| Shareholder equity |
527
|
270
|
278
|
301
|
210
|
-21
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-50
|
-103
|
-61
|
-65
|
36
|
-2
|
|
| Depreciation |
6
|
6
|
4
|
3
|
1
|
0
|
|
| Cash from Investing |
-214
|
25
|
-261
|
-10
|
-6
|
-3
|
|
| Capex |
4
|
7
|
6
|
10
|
6
|
3
|
|
| Cash from Financing |
372
|
76
|
40
|
143
|
167
|
70
|
|
| Stock Issued |
370
|
75
|
39
|
142
|
168
|
-1
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-318
|
-73
|
-331
|
-80
|
-24
|
1
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
9.6
|
8.1
|
8.0
|
11.3
|
9.2
|
7.3
|
|
| Financial Leverage D/E |
0.07
|
0.07
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-38.7%
|
-40.7%
|
-67.7%
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available